August 4, 2024
Powerhouse Therapeutics was formed to advance PH102 and selected solid-tumor cell therapy programs toward the clinic.
The Huang Lab announced the formation of Powerhouse Therapeutics, a biotechnology startup created to advance PH102 and a subset of the lab’s solid-tumor cell therapy portfolio.
The company focuses on translational development, manufacturing readiness, and moving key programs closer to clinical use.
More news
Feb 25, 2026
The Huang Lab received support to advance preclinical development of PH102 for hepatocellular carcinoma, reinforcing the lab’s translational focus.
Read articleOct 1, 2025
Vincent Pham will present Huang Lab research at the 2025 San Antonio Liver Cancer Symposium.
Read articleSep 10, 2025
Dr. Gang Huang will present the lab’s latest work on PH102 at the 2025 La Frontera Symposium.
Read article